VANCOUVER, Aug. 4 /CNW/ - Heart Force Medical Inc., a Vancouver-based
company that is developing a non-invasive cardiac performance monitor,
announced today that it has received USFDA Clearance for its digital
Ballistocardiograph (dBG (TM)).
"This further confirms the value of the dBG. We already have Health
Canada approval. Receiving certification from the USFDA, which is accepted as
the International Standard for regulatory compliance, gives us unfettered
access to the US Market. This allows us to fully define how our product will
be best used to assist physicians in their assessment of patients' cardiac
performance", said Dr. Geoff Houlton, Heart Force Medical's President and CEO.
"We are currently evaluating a number of business options that will enable HFM
to generate revenues for the dBG 300 as quickly as possible."
"We have seen the benefits of this device in assessing cardiac
performance in athletes, now we must focus on addressing physicians' and
patients' needs. We believe the dBG 300 could provide significant benefit for
monitoring patients in critical care as well as in assessing cardiac
performance in a wide variety of patients and situations", said Dr. Edward
Busse, Heart Force's Chief Medical Officer.
About Heart Force
Privately-held Heart Force Medical Inc. has its headquarters in Vancouver
and is in the business of developing non-invasive medical devices to assess
cardiac performance by measuring and monitoring the mechanical action of the
heart. The Heart Force dBG 300 device is a standalone, portable unit
containing sophisticated digital sensors.
For further information:
For further information: visit www.heartforcemedical.com, or contact:
email@example.com, Dr Geoff Houlton, (778) 989-7080